How is eplerenone different from spironolactone?

Eplerenone is more selective — far less breast tenderness and hormonal side effects — with similar potassium-sparing action. It's used mainly in heart failure after heart attack. Both need potassium monitoring; finerenone is the newer kidney-friendly option in diabetic CKD.

Mineralocorticoid receptor antagonist (potassium-sparing)

Eplerenone and Kidneys and Kidneys

Brand names: Inspra • Drug class: Mineralocorticoid receptor antagonist (potassium-sparing)

Eplerenone is a selective aldosterone blocker for heart failure after MI — with less hormonal side effects than spironolactone. Like all MR antagonists, its kidney-related risk is hyperkalemia, requiring potassium monitoring in CKD.

How it affects the kidneys

Eplerenone blocks aldosterone and reduces potassium excretion — hyperkalemia is the main concern in CKD. It's more selective than spironolactone (less gynecomastia) but the potassium risk is comparable. In diabetic CKD, the newer nonsteroidal finerenone provides similar blockade with better potassium tolerability and proven kidney protection (FIDELIO-DKD).

Evidence at a glance

EPHESUS trial: eplerenone reduced mortality in post-MI heart failure

EPHESUS (Pitt B et al., NEJM 2003), 2003

Hyperkalemia is the dose-limiting toxicity — risk rises as eGFR falls

Clinical trials + real-world data, 2022

Renal dosing guidance

Start 25 mg daily; increase to 50 mg if potassium stays <5.0. Contraindicated when CrCl <30 or potassium >5.5 at start. Check potassium within 3-5 days of starting and after any dose change; recheck regularly in CKD. Avoid with strong CYP3A4 inhibitors (ketoconazole, clarithromycin).

Check your kidney function